HOME >> BIOLOGY >> NEWS
Unusual data shed new light on brain and inhibiting behavior

ndary object, van Donkelaar said. "My initial reaction was to just throw them out," he said. "In adult studies there are so few multiple saccades that they are statistically insignificant, maybe just 5 percent of the time and attributed to mistakes by the participants. But in these results, we were seeing multiple saccades in 25 percent of the trials. It was a complete surprise. So we started asking what was happening and what it means."

Looking at and comparing the four age groups let the researchers recognize a trend. The 4- to 6-year-old children had difficulty stopping themselves from looking at a secondary object placed into their peripheral vision. They also initiated multiple saccades at a rapid pace and in much higher levels than adults, and did so 150 milliseconds sooner than adults, "which in brain time is an eternity," van Donkelaar said.

"In the 4-to-6-year-old and the 7-to-9-year-old groups, there was a similar relationship. The younger kids had a lot of trouble keeping their eyes fixated on the original target, but that problem was much more muted in the 7- to 9-year olds," he said.

The data appear to be tapping into the relationship between the frontal cortex, where decision-making skills develop, and how a decision influences the brain stem that controls eye movements, van Donkelaar said. "What we think is happening is that these multiple saccade trials are initiated so quickly that the frontal cortex isn't playing much of a role in the signaling of the brain stems in younger children," he said.

So how do the new findings fit into the group's overall research? It is believed that for cerebral palsy patients the development of the cortex will be delayed well beyond childhood. Thus eye movements and focusing along with other components involved in motor control may explain why it's more difficult for a cerebral palsy patient than a healthy adult to successfully pick up an object and manipulate it. Simply put, the
'"/>

Contact: Jim Barlow
jebarlow@uoregon.edu
541-346-3481
University of Oregon
15-Aug-2006


Page: 1 2 3

Related biology news :

1. Unusual three-drug combo inhibits growth of aggressive tumors
2. Unusual mechanism keeps repair protein accurate
3. Unusual RNAs linked to chronic leukemia, may help treat it
4. Unusual antibiotics show promise against deadly superbugs
5. Unusual reproductive behavior of odd ants surprises scientists
6. Other highlights in the Aug. 7 JNCI
7. Research team enlightens the reasons for severe blindness
8. Coelacanth fossil sheds light on fin-to-limb evolution
9. Molecule blocks gene, sheds light on liver cancer
10. ESA mission highlighted at remote sensing conference
11. Surprising new species of light-harvesting bacterium discovered in Yellowstone

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/23/2020)... ... June 23, 2020 , ... ... monoclonal antibody development services, today announced that the company has received ISO9001:2015 ... the pharmaceutical, diagnostics, and research industries. The decision to pursue ISO9001 accreditation ...
(Date:6/23/2020)... ... , ... In its June 22 online post, business and technology news platform ... Ph.D., founder and director of stem cell biotechnology company Asymmetrex . Superb Crew ... starting July 5 it would begin offering free tissue stem cell counting ...
(Date:6/13/2020)... ... June 11, 2020 , ... Bode Technology (Bode), ... forensic genealogy team. Bode’s Forensic Genealogy Service (FGS) continues to deliver ... analysis methods. The team has added experienced genealogists, each having over a decade ...
Breaking Biology News(10 mins):
(Date:6/28/2020)... ROCKY HILL, Conn. (PRWEB) , ... June 25, ... ... systems company formed to advance photodynamic therapy for treating cancer, today announced the ... Buffalo, New York (“Roswell Park”). The agreement provides Lumeda globally exclusive rights ...
(Date:6/23/2020)... ... , ... Kerafast Inc. , developers of an online ... of the Delta-G-VSV Pseudotyping System for coronavirus research applications. The system, developed by ... entry and COVID-19 vaccine effectiveness at just biosafety level 2 (BSL-2) containment. , ...
(Date:6/23/2020)... ... 2020 , ... Regen Suppliers, the one stop shop for ... get the fourth unit free with no limit on the amniotic derived exosomes. ... have been a game changer for regenerative therapies. The products are manufactured at ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... therapies, today announced that it has filed an Investigational New Drug application (IND) ... clinical trial of its lead drug candidate NBTX-001 in patients with panic disorder ...
Breaking Biology Technology:
Cached News: